



Synthesis and screening of a CaaL peptide library versus FTase reveals a surprising number of substrates

Amanda J. Krzysiak^a, Animesh V. Aditya^a, James L. Hougland^b, Carol A. Fierke^b, Richard A. Gibbs^{a,*}

^aDepartment of Medicinal Chemistry and Molecular Pharmacology and Center for Cancer Research, Purdue University, West Lafayette, IN 47907, United States

^bDepartment of Chemistry, University of Michigan, Ann Arbor, MI 48109, United States

ARTICLE INFO

Article history:

Received 22 July 2009

Revised 3 November 2009

Accepted 5 November 2009

Available online 12 November 2009

Keywords:

Farnesylation

Geranylgeranylation

Peptide synthesis

Enzymes

Post-translational modification

ABSTRACT

Proteins bearing a CaaL sequence are typically geranylgeranylated to enable their proper localization and function. We found that many of the dansyl-GCaaL peptides representing mammalian CaaL proteins can be farnesylated by FTase. This result may have important implications for prenylated protein biology.

© 2009 Elsevier Ltd. All rights reserved.

It is predicted that more than 60 mammalian proteins are farnesylated, and a similar number are monogeranylgeranylated^{1,2} (Fig. 1). Two enzymes catalyze these modifications: farnesyltransferase and geranylgeranyltransferase-I (FTase and GGTase-I). In both cases, the isoprenoid is attached to the cysteine in a C-terminal 'Ca₁a₂X' sequence. While the 'a' residues guide substrate ability,^{3,4} the X position a selectivity factor for FTase versus GGTase-I.¹⁸ Those peptides bearing X residues of Ser, Gln, and Met are farnesylated (Ras proteins and others) and those bearing Leu are geranylgeranylated (Rho proteins and others). However, it has been demonstrated that RhoB, with a C-terminal CKVL CaaX box, can be prenylated by either FTase or GGTase-I in mammalian cells.^{5,6}

FTase emerged as a drug target when it was discovered that Ras proteins are farnesylated. FTase inhibitors (FTIs) have been developed and clinically evaluated.⁷ Unfortunately, many tumors are resistant to FTIs, due in part to the ability of K-Ras to serve as a substrate for either FTase or GGTase-I.^{8,9} Interest in GGTase-I inhibitors (GGTIs) as anti-cancer agents is gaining momentum,¹⁰ as genetic ablation of GGTase I leads to tumor regression in mice with K-Ras-driven lung tumors.¹¹ GGTIs have been developed by several groups, and clinical trials began in 2009 with GGTI-2148.¹² It is not known if the alternate farnesylation of any geranylgeranylated proteins would confer resistance to GGTIs, and this is a key question with regard to their evaluation.¹⁰ As a comple-




Figure 1. Prenylation (either farnesylation by FTase or geranylgeranylation by GGTase-I) of Ras-related proteins, and subsequent processing events.

* Corresponding author.

E-mail address: rgibbs@purdue.edu (R.A. Gibbs).

ment to proteomic methods,^{13,14} we have employed peptide libraries to evaluate FTase substrate specificity.^{3,23} In this study, we screened 41 dansyl-GCaaL (DnGCaaL) peptides versus FTase, and found a surprising number of efficient substrates.

The DnGCaaL peptides evaluated were chosen in one of two ways. First, a number of sequences are predicted as GGTase-I substrates based on the crystal structure of this enzyme.^{1,2} Second, additional GGTase I candidate substrate sequences were identified from database searches, in particular focusing on sequences possessing diverse 'a' residues. The 41-member DnGCaaL library was prepared using standard Fmoc solid phase peptide synthesis protocols, with Fmoc-Leu-Wang resin, Fmoc-amino acids, dansyl-Gly, and HBTU/HOBt couplings.

A spectrofluorimetric assay was used to determine FTase substrate activity for the DnGCaaL peptides.^{3,15} The FTase substrate DnGCVL, representing the CaaX box of H-Ras, was used as the control. Briefly, 3 μ M DnGCaaL peptide and 9 μ M FPP are combined, and farnesylation is initiated with the addition of recombinant mammalian FTase (0.05 μ M).²⁴ Peptide farnesylation is measured after 30 min via the relative fluorescence increase (RFI, Table 1, column 3) in emission at 535 nm. The formation of farnesylated product was confirmed by HPLC (Table 1, column 4) after 60 min. The prototypical FTase substrate DnGCVL exhibits complete turnover to farnesylated product under these conditions after 15 min.

The data from the DnGCaaL peptide screen are presented in Table 1. Based on their FTase substrate ability, the peptide sequences can be separated into four categories. Ten peptides (Table 1, entries 1–10) are good FTase substrates, using our previously reported screening conditions.³ They exhibit activity in the fluorescence assay between 9% and 101% that of DnGCVL, and their substrate ability is confirmed via the HPLC assay. Nine additional peptides (Table 1, entries 11–19) are poor FTase substrates. They exhibit <5% of the activity of DnGCVL in the fluorescence assay, and they demonstrate partial substrate conversion to product by HPLC. Five peptides (Table 1, entries 20–24) are marginal substrates, exhibiting some peptide product by HPLC but no significant activity by the fluorescence assay. The remaining 17 CaaL peptides (entries 25–41) exhibit no substrate ability with FTase. To provide more detailed information on the most effective substrates (Table 1, entries 1–10), k_{cat}/K_m values were determined for each one under reaction conditions identical to those reported previously.⁴ Each peptide was validated as an FTase substrate. However, the initial screening results overstated their relative efficiencies, with k_{cat}/K_m values ranging from 3% to 28% that of the prototypical FTase substrate DnGCVL.⁴

The current understanding of FTase peptide specificity holds that the X residue of the $\text{Ca}_1\text{a}_2\text{X}$ sequence is the primary determinant for FTase/GGTase-I substrate discrimination, and that CaaL peptides would likely not be FTase substrates.^{1,2,18} This proved not to be correct with the DnGCaaL library. It was previously also predicted with regard to the a_1 and a_2 positions of the CaaX box that the enzyme will accept any amino acid at the a_1 position, but hydrophobic residues (e.g., Ile, Leu, Val) are preferred for the a_2 residue. Our results support this general a_1/a_2 model; of the 19 good/poor substrates, 18 contain Val, Leu, or Ile at the a_2 position. However, the factors that influence CaaL processing by FTase are quite subtle. In particular, note that the Ca_1IL sequence, which is found on nine peptides in the library, is preferred by FTase. The seven most active CaaL peptides (Table 1, entries 1–7) contain this sequence, and CLIL and CPIL are also confirmed substrates. Conversely, a number of poor and marginal FTase substrates bear potentially favorable Val and Leu residues at the a_2 position. Another surprising finding is that DnGCLML is a good FTase substrate (Table 1, entry 10). Methionine is rare as an a_2 residue in a CaaX sequence, with only four examples found among the proposed FTase or GGTase I substrates.¹ Note that in our earlier study on a

DnGCaaS library,³ several unusual polar residues were accepted at the a_2 position, but that is not the case with the DnGCaaL library.

PRENbase is a database based on an algorithm that uses the 15 C-terminal amino acids to predict FTase and GGTase-I substrates.¹⁶ This tool proved quite effective, predicting the FTase substrate ability for 17 of the 19 good and poor CaaL substrates. The two exceptions were the CNIL and CRLL sequences (Table 1, entries 6 and 13). Another interesting feature of the PRENbase analysis is that the CaaL sequence CLML (Table 1, entry 10) is correctly predicted to be FTase substrate, but is not predicted to be a GGTase I substrate.

These data shed light on the tolerance of FTase for CaaL peptide sequences. We did not anticipate that a substantial number of these peptides would be FTase substrates. Although FTase has a second X residue binding site for hydrophobic side chains, structural analysis seemed to indicate that phenylalanine bound best and leucine bound only with steric clashes.¹ However, an early study by the Merck group on the substrate activity of CaaX peptides had demonstrated that certain CaaL peptides are farnesylated by FTase.¹⁷ More recent detailed kinetic studies demonstrated that DnTKCVIL was an FTase substrate under single turnover conditions, but did not exhibit efficient turnover under steady-state conditions.¹⁸ The difference in substrate activity between DnGCVL (Table 1, entry 4) and DnTKCVIL is presumably due to the upstream lysine that decreases rate constants for formation of product and product release.¹⁹

Many geranylgeranylated proteins play key roles in cancer cell growth and signaling, and thus are potential targets for GGTIs. However, alternative farnesylation of these sequences would be a complicating factor. The only CaaL protein that is a well-described FTase substrate is RhoB,^{5,6} although the proteomic studies of Zhao and coworkers indicate that the CVLL and CKAL sequences may be farnesylated *in vivo*.¹³ Surprisingly, the CKVL and CVLL sequences are relatively modest FTase substrates in our assay, suggesting that other CaaL proteins may be farnesylated in the cell. Hildebrandt and coworkers have carried out an extensive proteomic examination of the post-translational modification of G-protein γ -subunits from bovine brain.²⁰ The γ -2 subunit, bearing the CAIL CaaX motif (Table 1, entry 2) is both geranylgeranylated and farnesylated in the cell, in accord with our biochemical results. However, the γ -7 and γ -12 subunits, bearing the CIL CaaX motif (Table 1, entry 1), did not exhibit farnesylation in the proteomic study. Two studies have recently been carried out on the abilities of various Ras-related proteins to be alternatively prenylated.^{21,22} In the first study, Sebt and coworkers reported that RalA did not exhibit cellular farnesylation by FTase.²¹ These results are in contrast to ours where the RalA CaaX box (DnGCCIL Table 1, entry 3) is an efficient FTase substrate. This discrepancy could be due to unfavorable residues for FTase substrate ability upstream of the CCIL sequence. Very recently, Der and co-workers have published the results of a second study on the alternative prenylation of several additional CaaL-bearing Ras-related proteins.²² It was demonstrated that Rac1 is solely a GGTase-I substrate, while Rif/RhoF exhibits dual FTase/GGTase-I substrate ability behavior in cellular evaluation. Both proteins bear a CLLL CaaX box, which is a poor FTase substrate in our enzymatic assay (entry 15). Note that Rac1 bears a lysine residue adjacent to the prenylated cysteine residue, while Rif/RhoF bears a leucine residue. Taking these cellular studies together with our biochemical results, it is clear that the residues upstream of the CaaL box play an important role in the FTase substrate ability of cellular proteins.

GGTase-I catalyzes the prenylation of many crucial signaling proteins, and is also emerging as an important antitumor drug target. Our studies have shown that ten DnGCaaL peptides function as efficient substrates for FTase, and several other sequences can also be accepted as substrates. These results provide important and unexpected new insights into the biochemical substrate specificity

Table 1
Evaluation of DnGCaaL library versus FTase

	CaaX ^a	Protein ^b	RFI ^c	HPLC ^d	k_{cat}/K_m^e (mM ⁻¹ s ⁻¹)	PRENbase FT ^f	PRENbase GGT ^g
1	CIIL	F-box and leucine-rich repeat protein 20/G Protein γ -7 subunit*/G Protein γ -12 subunit*	1.01	+++	43 ± 8	++(0.254)	+++ (2.78)
2	CAIL	G protein γ -2 subunit**	0.71	+++	27 ± 2	++(0.583)	+++ (3.18)
3	CCIL	Rod cGMP-specific 3',5'-cyclic PDE β -subunit*/RalA*	0.61	+++	23 ± 3	++(0.985)	+++ (2.7)
4	CVIL	Rap2B*/M-Ras*/F-box & leucine-rich repeat prot. 2	0.52	+++	47 ± 8	++(0.796)	+++ (2.55)
5	CTIL	G protein γ -4 subunit/G protein γ -13 subunit/2',5'-oligoadenylate synthetase 1/retinitis pigmentosa GTPase regulator isoforms 1, 2, 4/F-box protein 10	0.45	++	33 ± 7	++(0.735)	+++ (3.13)
6	CNIL	Interferon induced guanylate binding protein 2*	0.22	++	12 ± 0.9	-(-3.64)	++ (0.881)
7	CSIL	NIM1 Kinase	0.18	+++	5 ± 1	+(-1.07)	++ (0.73)
8	CILL	Rho G*	0.15	++	8 ± 2	+(-3.11)	++ (1.86)
9	CCVL	Schlafen-like1	0.11	+++	7 ± 1	+(-0.50)	++ (0.796)
10	CLML	cone cGMP-specific 3',5'-cyclic PDE β -subunit	0.09	++	8.1 ± 0.5	+(-1.33)	-(-3.16)
11	CLIL	DnaJ (Hsp40)homolog, subfamily B, member	<0.05	++		++(0.76)	+++ (2.95)
12	CKVL	Rho B**	<0.05	+		+(-1.08)	+(-1.68)
13	CRLI	Phospholipase D family, member 3	<0.05	+		-(-2.05)	-(-5.03)
14	CLVL	Rho A*	<0.05	+		++(0.306)	+++ (2.253)
15	CLLL	Rac1*/Rif**/G protein coupled receptor kinase 7	<0.05	+		++(0.043)	+++ (2.33)
16	CALL	Heterotrimeric G-protein γ -3 subunit*	<0.05	+		+(-428)	++ (1.92)
17	CVLL	cdc42*	<0.05	+		++(0.696)	+++ (+2.95)
18	CCLL	Ral B*/Mannose-6-phosphate isomerase	<0.05	+		++(0.281)	++ (1.81)
19	CPIL	Rho C*	<0.05	+		+(-0.977)	+++ (2.61)
20	CSVL	Rab 18	0	+		+(-0.061)	++ (3.20)
21	CTLL	Aldehyde dehydrogenase	0	+		+(-1.81)	+(-1.15)
22	CSLL	Rab 8B/Rac2*	0	—		+(-0.106)	++ (1.71)
23	CQLL	Rap1B*	0	—		+(-0.52)	++ (2.3)
24	CLQL	RacX	0	—		+(-0.38)	-(-4.03)
25	CHPL	Protein C20orf24(Rab-5-interacting protein)	0	---		-(-7.89)	-(-13.43)
26	CNPL	Inositol phosphatase*	0	---		-(-6.57)	-(-8.78)
27	CGGL	Glycerol 3-P dehydrogenase	0	---		-(-5.89)	-(-8.84)
28	CGQL	Cyclophilin	0	---		-(-3.05)	-(-11.52)
29	CLGL	MAD prot./MAD dimer	0	---		-(-4.15)	-(-4.27)
30	CTAL	Phosphate transport	0	---		-(-4.85)	-(-6.25)
31	CSTL	CASP8 and FADD-like precursor (splice isoform 10)	0	---		-(-2.67)	-(-8.23)
32	CAYL	Mitochondrial 28S Ribosomal protein S29	0	---		-(-5.75)	-(-5.80)
33	CSFL	G-Protein γ -5 subunit*	0	---		-(-5.54)	-(-5.16)
34	CHAL	NUDT9	0	---		-(-7.4)	-(-8.3)
35	CGCL	Mouse nodal homolog precursor	0	---		-(-3.81)	-(-8.99)
36	CMEI	Sulfotransferase family, cytosolic, 1C, member 2-Rat	0	---		-(-6.99)	-(-9.76)
37	CVGL	Butyrylcholinesterase	0	---		-(-3.79)	-(-3.14)
38	CEKL	Lactalbumin, alpha-	0	---		-(-10.41)	-(-15.20)
39	CQNL	RAB11B	0	---		-(-2.88)	-(-8.18)
40	CSQL	STEAP1	0	---		-(-2.62)	-(-8.51)
41	CCSL	Interleukin 17 receptor B	0	---		-(-2.15)	-(-5.74)

^a All peptides have the sequence DnG-CxxL.

^b Protein(s) bearing the corresponding CaaL sequence at the carboxyl terminus. * Proteins known to be geranylgeranylated; ** Proteins known to be geranylgeranylated and farnesylated.

^c RFI = relative fluorescence increase at 535 nm after 30 min in the spectrofluorimetric assay, with increase seen for DnGCVLS set at RFI = 1.0. Assays were performed using FPP (9 μ M), dansylated-peptide (3 μ M) and 50 nM FTase in 52 mM Tris at pH 7.5 with 5.8 μ M MgCl₂, and 12 μ M ZnCl₂.

^d Formation of farnesylated peptide product after 60 min incubation with FTase as determined by HPLC analysis. +++, complete conversion of peptide to farnesylated product; ++, nearly complete conversion to product; +, 25%–50% conversion to product; —, less than 25% conversion; —, no product observed.

^e The steady-state kinetic parameters were determined at saturating FPP (10 μ M) and varying peptide concentrations (0.2–10 μ M peptide) in 20–100 nM FTase. Kinetics were determined for FTase from a time-dependent increase in fluorescence (λ_{ex} 340 nm, λ_{em} 520 nm) upon farnesylation of the dansylated peptide. Assays were performed 50 mM HEPPO pH 7.8, 5 mM tris(2-carboxyethyl)phosphine (TCEP), and 5 mM MgCl₂ at 25 °C in a 96-well plate (Corning). Peptides were incubated in reaction buffer for 20 min prior to initiation by addition of FTase and FPP, with the FTase concentration at least fivefold lower than the peptide concentration. Fluorescence was measured and converted to k_{cat} values as described in our recent publication (Ref. 4). Under these same conditions, DnGCVLS k_{cat}/K_m = 170 ± 30 mM⁻¹ s⁻¹.

^f PRENbase prediction for the FTase substrate ability of the sequence XXXXXXXXXXXXCaal, for the first protein listed.

^g PRENbase prediction for the GGTase-I substrate ability of the sequence XXXXXXXXXXXXCaal, for the first protein listed, as described.

of FTase. In combination with the recent evaluation of the prenyl-transferase specificity of CaaL-bearing proteins in cells,^{20–22} our results provide an indication of the importance of upstream residues in FTase/GGTase-I selectivity. It may be of significant interest to evaluate the prenylation of other proteins indicated as potential FTase substrates in Table 1.

Acknowledgements

This work was supported by NIH grants R01CA78819 (R.A.G.), R01GM40602 (C.A.F.), F32GM78894 (J.L.H.), and P30 CA21368 (Purdue Center for Cancer Research). A.J.K. and A.V.A. were supported in part by PRF fellowships.

References and notes

- Reid, T. S.; Terry, K. L.; Casey, P. J.; Beese, L. S. *J. Mol. Biol.* **2004**, *343*, 417.
- Lane, K. T.; Beese, L. S. *J. Lipid Res.* **2006**, *47*, 681.
- Krzysiak, A. J.; Scott, S. A.; Hicks, K. A.; Fierke, C. A.; Gibbs, R. A. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 5548.
- Hougland, J. L.; Lamphear, C. L.; Scott, S. A.; Gibbs, R. A.; Fierke, C. A. *Biochemistry* **2009**, *48*, 1691.
- Lebowitz, P. F.; Casey, P. J.; Prendergast, G. C.; Thissen, J. A. *J. Biol. Chem.* **1997**, *272*, 15591.
- Baron, R.; Fourcade, E.; Lajoie-Mazenc, I.; Allal, C.; Couderc, B.; Barbaras, R.; Favre, G.; Faye, J.-C.; Pradines, A. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 11626.
- Basso, A. D.; Kirschmeier, P. T.; Bishop, W. R. *J. Lipid Res.* **2006**, *47*, 15.
- Whyte, D. B.; Kirschmeier, P.; Hockenberry, T. N.; Nunez-Oliva, I.; James, L.; Catino, J. J.; Bishop, W. R.; Pai, J.-K. *J. Biol. Chem.* **1997**, *272*, 14459.
- Rowell, C. A.; Kowalczyk, J. J.; Lewis, M. D.; Garcia, A. M. *J. Biol. Chem.* **1997**, *272*, 14093.
- Philips, M. R.; Cox, A. D. *J. Clin. Invest.* **2007**, *117*, 1223.
- Sjogren, A.-K. M.; Andersson, K. M. E.; Liu, M.; Cutts, B. A.; Karlsson, C.; Wahlstrom, A. M.; Dalin, M.; Weinbaum, C.; Casey, P. J.; Tarkowski, A.; Swolin, B.; Young, S. G.; Bergo, M. O. *J. Clin. Invest.* **2007**, *117*, 1294.
- Kazi, A.; Carie, A.; Blaskovich, M.; Bucher, C.; Thai, V.; Moulder, S.; Peng, H.; Carrico, D.; Pusateri, E. E.; Pledger, W. J.; Berndt, N.; Hamilton, A. D.; Sebt, S. M. *Mol. Cell. Biol.* **2009**, *29*, 2254.
- Kho, Y.; Kim, S. C.; Jiang, C.; Barma, D.; Kwon, S. W.; Cheng, J.; Jaunbergs, J.; Weinbaum, C.; Tamanoi, F.; Falck, J.; Zhao, Y. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 12479.
- Nguyen, U. T. T.; Guo, Z.; Delon, C.; Wu, Y.; Deraeve, C.; Franzel, B.; Bon, R. S.; Blankenfeldt, W.; Goody, R. S.; Waldmann, H.; Wolters, D.; Alexandrov, K. *Nat. Chem. Biol.* **2009**, *5*, 227.
- Cassidy, P. B.; Dolence, J. M.; Poulter, C. D. *Methods Enzymol.* **1995**, *250*, 30.
- Maurer-Stroh, S.; Koranda, M.; Benetka, W.; Schneider, G.; Sirota, F. L.; Eisenhaber, F. *PLoS Comp. Biol.* **2007**, *3*, e66.
- Moore, S. L.; Schaber, M. D.; Mosser, S. D.; Rands, E.; O'Hara, M. B.; Garsky, V. M.; Marshall, M. S.; Pompliano, D. L.; Gibbs, J. B. *J. Biol. Chem.* **1991**, *266*, 14603.
- Hartman, H. L.; Hicks, K. A.; Fierke, C. A. *Biochemistry* **2005**, *44*, 15314.
- Fiordalisi, J. J.; Johnson, R. L.; Weinbaum, C.; Sakabe, K.; Chen, Z.; Casey, P. J.; Cox, A. D. *J. Biol. Chem.* **2003**, *278*, 41718.
- Cook, L. A.; Schey, K. L.; Wilcox, M. D.; Dingus, J.; Ettling, R.; Nelson, T.; Knapp, D. R.; Hildebrandt, J. D. *Mol. Cell. Proteom.* **2006**, *5*, 671684.
- Falsetti, S. C.; Wang, D.; Peng, H.; Carrico, D.; Cox, A. D.; Der, C. J.; Hamilton, A. D.; Sebt, S. M. *Mol. Cell. Biol.* **2007**, *27*, 8003.
- Roberts, P. J.; Mitin, N.; Keller, P. J.; Chenette, E. J.; Madigan, J. P.; Curring, R. O.; Cox, A. D.; Wilson, O.; Kirschmeier, P. T.; Der, C. J. *J. Biol. Chem.* **2008**, *283*, 25150.
- Hougland, J.L.; Hicks, K.A.; Hartman, H.L.; Kelly, R.A.; Watt, T.J.; Fierke, C.A. *J. Mol. Biol.* **2009**, in press.
- Zimmerman, K. K.; Scholten, J. D.; Huang, C.-c.; Fierke, C. A.; Hupe, D. J. *Protein Expr. Purif.* **1998**, *3*, 395.